Boston, MA 06/13/2013 (wallstreetpr) – The share prices of Celsion Corporation (NASDAQ:CLSN) had declined by 11.32 percent to close at $1.41 per share for the end of last trading session on Wednesday. The shares of the company had been trading in the range of $1.25 to $1.43 per share during the day. The shares of Celsion Corporation (NASDAQ:CLSN) had recorded 52 week low price level of $0.75 per share and 52 week low price level of $9.44 per share.
Celsion Corporation (NASDAQ:CLSN) is a bio pharmaceutical company with primary focus in the field of oncology and is involved in the development and commercialization of treatment therapies for those suffering from difficult to treat forms of cancer. The company is presently involved in the development of its leading drug candidate, ThermoDox which is being evaluated for the treatment of various forms of cancer such as primary liver cancer, colorectal liver metastasis and recurrent chest wall breast cancer in different phases of clinical trials.
Celsion Corporation (NASDAQ:CLSN) has various research, license and commercialization agreements with leading institutions such as the National Institute of Health, Duke University Medical Center. University of Hong Kong, University of Pisa, the UCLA Department of Medicine, Beijing Cancer Hospital and the University of Oxford.
The shares of Celsion Corporation (NASDAQ:CLSN) had recently been declining in prices with heavy trading volumes. The company had witnessed the trade of 11.14 million shares on Wednesday, while the average trading volume is at 7.62 million shares per day.
Celsion Corporation (NASDAQ:CLSN) presently holds 37.30 million shares outstanding in the market with an institutional ownership of 34 percent of its holdings.
